Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002868 · ClinicalTrials.gov registry record · Phase 3
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
A Phase 3 study of Leukemia, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 744
- Enrollment target
- 3
- Study locations
NCT00002868 is a Phase 3 study of Leukemia that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 744 participants, above the 484-participant average among 233 other Leukemia trials with a reported enrollment target (54% higher). The trial reports 3 study locations across 2 states.
The verdict
NCT00002868, a Phase 3 study of Leukemia, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 744 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining interferon alfa with high-dose chemotherapy and peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without peripheral stem cell transplantation in treating patients who have newly diagnosed chronic myelogenous leukemia in chronic phase.
Conditions Studied
Interventions
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG busulfan
- BIOLOGICAL recombinant interferon alfa
Study Locations (3)
New Jersey
- Hackensack University Medical Center - Hackensack
- Riverview Medical Center - Booker Cancer Center - Red Bank
Scotland
- Royal Infirmary - Glasgow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 1997-11-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002868
The ClinicalTrials.gov registry entry for NCT00002868 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 744 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 484-participant average among 233 other Leukemia trials with a reported enrollment target (54% higher). The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which etoposide is the first listed.
NCT00002868 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Scotland.
Frequently Asked Questions
What is clinical trial NCT00002868 about?
NCT00002868 is a clinical study titled "Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia". RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining interferon alfa with high-dose chemotherapy and peripheral stem cell transplantation may allow the doctor ...
What is the current status of trial NCT00002868?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 744 participants. The study started on 1997-11-20.
What conditions does trial NCT00002868 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00002868?
The interventions under investigation include: etoposide (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG), busulfan (DRUG), recombinant interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002868?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002868 being conducted?
This trial has 3 study locations across New Jersey, Scotland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.